Look back at pharma news in the week to June 11, 2021

13 June 2021

By Barbara Obstoj-Cardwell. Editor

The US Food and Drug Administration last Monday finally approved the use of Biogen’s New Drug Application (NDA) for the use of aducanumab, now trade-named Aduhelm, for the treatment of Alzheimer’s disease. Novartis released positive Phase III data for its iptacopan as a treatment for a rare kidney disease. Last Wednesday, Ocugen revealed that, following a meeting with the FDA, it is seeking approval for its COVID-19 vaccine candidate, Covaxin, through a full Biological License Application (BLA), rather than the faster emergency use authorization process, suggesting that, with the number on vaccines already cleared for EUA, the agency is tightening up the rules. There was negative news from Vertex on Thursday, when the company announced that, although its rare disease candidate VX-864 met its primary endpoint in the latest trial, added to previous results it looks unlikely to provide substantial clinical benefit, so has dropped its development.

Big news with Aduhelm approval in Alzheimer’s

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK